Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice

Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice

Objective To show the safety and efficacy of subcutaneous (SC) methotrexate (MTX) compared to oral MTX, alternative disease‐modifying antirheumatic drugs (DMARDs) monotherapy, biologic monotherapy, and combinations (conventional and biologic combination groups) in routine clinical practice. Methods...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis care & research (2010) 2021-09, Vol.73 (9), p.1306-1311
Hauptverfasser: Li, Christien K. H., Baker, Kenneth, Jones, Tania, Coulson, Elizabeth, Roberts, Andrew, Birrell, Fraser
Format: Artikel
Sprache:eng
Schlagworte:
Administration, Oral
Adverse events
Aged
Alanine
Alanine transaminase
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - adverse effects
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - immunology
Biological Products - administration & dosage
Clinical medicine
Databases, Factual
Drug Therapy, Combination
Female
Humans
Immunomodulators
Injections, Subcutaneous
Leukocytes (neutrophilic)
Male
Methotrexate
Methotrexate - administration & dosage
Methotrexate - adverse effects
Middle Aged
Neutropenia
Patient Safety
Patients
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To show the safety and efficacy of subcutaneous (SC) methotrexate (MTX) compared to oral MTX, alternative disease‐modifying antirheumatic drugs (DMARDs) monotherapy, biologic monotherapy, and combinations (conventional and biologic combination groups) in routine clinical practice. Methods Clinical and laboratory data were retrospectively analyzed for rheumatology clinic attendances at a large Northeast England hospital trust between January 2014 and January 2018. Rates of adverse events and stop events (transaminitis [serum alanine aminotransferase level of >80 units/liter] or neutropenia [neutrophil count of
ISSN:2151-464X
2151-4658
DOI:10.1002/acr.24334